<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>350</serviceExecutionTime><Drug id="54740"><DrugName>lidocaine + tetracaine (local anesthesia), Crescita</DrugName><DrugNamesKey><Name id="42951696">Flexicaine</Name><Name id="42880999">Pliaglis</Name><Name id="42839100">TetraPeel</Name></DrugNamesKey><DrugSynonyms><Name><Value>lidocaine + tetracaine (local anesthesia), Nuvo</Value></Name><Name><Value>S-Caine Peel</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>TetraPeel</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>lidocaine + tetracaine</Value></Name><Name><Value>Pliaglis</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>ZS-2001</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Flexicaine</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>lidocaine + tetracaine (local anesthesia), Crescita</Value></Name><Name><Value>94-24-6</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>137-58-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1005570">ZARS Pharma Inc</CompanyOriginator><CompaniesPrimary><Company id="1120227">Crescita Therapeutics Inc</Company><Company id="27572">Taro Pharmaceuticals Inc (Canada)</Company><Company id="1092247">Cantabria Labs Spain</Company></CompaniesPrimary><CompaniesSecondary><Company id="1005570">ZARS Pharma Inc</Company><Company id="1040947">Galderma Laboratories LP</Company><Company id="15713">Nuvo Pharmaceuticals Inc</Company><Company id="16350">Galderma SA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1005570" type="Company"><TargetEntity id="4298093860" type="organizationId">Zars Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="1040947" type="Company"><TargetEntity id="4296572187" type="organizationId">Galderma Laboratories LP</TargetEntity></SourceEntity><SourceEntity id="1120227" type="Company"><TargetEntity id="5050638727" type="organizationId">Crescita Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="15713" type="Company"><TargetEntity id="4295862549" type="organizationId">Nuvo Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="16350" type="Company"><TargetEntity id="5000735483" type="organizationId">Galderma SA</TargetEntity></SourceEntity><SourceEntity id="27572" type="Company"><TargetEntity id="5000435040" type="organizationId">Taro Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="328" type="ciIndication"><TargetEntity id="10024758" type="MEDDRA"/><TargetEntity id="D000772" type="MeSH"/></SourceEntity><SourceEntity id="3300" type="ciIndication"><TargetEntity id="10036376" type="MEDDRA"/><TargetEntity id="D051474" type="MeSH"/><TargetEntity id="-1650985330" type="omicsDisease"/><TargetEntity id="17" type="siCondition"/></SourceEntity><SourceEntity id="498" type="Action"><TargetEntity id="358" type="Mechanism">Sodium Channel Blockers</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Topical anesthesia - US - Feb-2008</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="328">Topical anesthesia</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="3300">Postherpetic neuralgia</Indication></IndicationsSecondary><ActionsPrimary><Action id="498">Sodium channel inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1669">Local anesthetic</Action><Action id="2946">Analgesic</Action></ActionsSecondary><Technologies><Technology id="175">Drug combination</Technology><Technology id="558">Transdermal formulation</Technology><Technology id="611">Dermatological formulation</Technology><Technology id="612">Emulsion dermatological</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra><Ephmra><Code>N1B</Code><Name>ANAESTHETICS, LOCAL</Name></Ephmra></EphmraCodes><LastModificationDate>2019-07-02T20:28:34.000Z</LastModificationDate><ChangeDateLast>2019-07-03T00:00:00.000Z</ChangeDateLast><AddedDate>2006-01-09T16:11:07.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1120227" linkType="Company"&gt;Crescita&lt;/ulink&gt;, formed following the reorganization of &lt;ulink linkID="15713" linkType="Company"&gt;Nuvo Research&lt;/ulink&gt;  (now Nuvo Pharmaceuticals; following its acquisition of &lt;ulink linkID="1005570" linkType="Company"&gt;ZARS&lt;/ulink&gt; in May 2011) has developed and launched a transdermal cream formulation (which sets and can be peeled off), consisting of  lidocaine 70 mg plus tetracaine 70 mg (Pliaglis, S-Caine Peel, TetraPeel, ZS-2001, Flexicaine), as a topical anesthetic for use in superficial cosmetic procedures [&lt;ulink linkID="644099" linkType="Reference"&gt;644099&lt;/ulink&gt;], [&lt;ulink linkID="1190068" linkType="Reference"&gt;1190068&lt;/ulink&gt;], [&lt;ulink linkID="1533335" linkType="Reference"&gt;1533335&lt;/ulink&gt;], [&lt;ulink linkID="1739318" linkType="Reference"&gt;1739318&lt;/ulink&gt;]. By February 2008,  the peel had been launched in the US for cosmetic procedures such as dermal filler procedures, pulsed dye laser therapy, facial laser resurfacing and laser-assisted tattoo removal by Nuvo's former licensee &lt;ulink linkID="16350" linkType="Company"&gt;Galderma&lt;/ulink&gt;   [&lt;ulink linkID="878158" linkType="Reference"&gt;878158&lt;/ulink&gt;], but the drug was subsequently withdrawn in 2008 for manufacturing issues [&lt;ulink linkID="1184798" linkType="Reference"&gt;1184798&lt;/ulink&gt;]; however, following an approval of an sNDA it was launched again by Galderma in May 2013 [&lt;ulink linkID="1390467" linkType="Reference"&gt;1390467&lt;/ulink&gt;].  By December 2011, the drug had been launched in Argentina by Galderma  [&lt;ulink linkID="1408247" linkType="Reference"&gt;1408247&lt;/ulink&gt;]. In April 2013, the drug was launched in European countries by Galderma [&lt;ulink linkID="1408247" linkType="Reference"&gt;1408247&lt;/ulink&gt;]. In December 2015, Nuvo reacquired North American rights for the drug;Galderma would continue to market the drug in the US, Canada and Mexico during the transition period  [&lt;ulink linkID="1723148" linkType="Reference"&gt;1723148&lt;/ulink&gt;]. In March 2016, Nuvo was reorganized and Crescita was formed [&lt;ulink linkID="1739318" linkType="Reference"&gt;1739318&lt;/ulink&gt;]. In April 2017, &lt;ulink linkID="27572" linkType="Company"&gt;Taro Pharmaceuticals&lt;/ulink&gt; gained the rights to sell and distribute the Pliaglis, as well as a second-generation enhanced formulation, in the US; at that time, the drug was not available in the US  [&lt;ulink linkID="1921282" linkType="Reference"&gt;1921282&lt;/ulink&gt;]. In March 2018, the drug was re-launched in the US by Taro Pharmaceuticals [&lt;ulink linkID="2018265" linkType="Reference"&gt;2018265&lt;/ulink&gt;].   In April 2019, Crescita reacquired the rest-of-world rights  to Pliaglis from Galderma; at that time, the drug was only available in the US, Italy and Brazil and presumably withdrawn in the regions where it was previously launched. Later that month, Crescita licensed rights to &lt;ulink linkID="1092247" linkType="Company"&gt;Cantabria Labs&lt;/ulink&gt; for the drug in Italy, Portugal, France and Spain [&lt;ulink linkID="2145520" linkType="Reference"&gt;2145520&lt;/ulink&gt;]. In May 2019, Crescita planned to re-launch the drug in Canada in the second half of 2019 [&lt;ulink linkID="2169893" linkType="Reference"&gt;2169893&lt;/ulink&gt;]. In April 2019, Crescita was seeking to outlicense the drug for the rest of countries, including Mexico [&lt;ulink linkID="2145520" linkType="Reference"&gt;2145520&lt;/ulink&gt;], [&lt;ulink linkID="2169893" linkType="Reference"&gt;2169893&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Crescita  was previously developing the drug as ZS-2001 for potential use as an analgesic in postherpetic neuralgia (PHN) [&lt;ulink linkID="877912" linkType="Reference"&gt;877912&lt;/ulink&gt;], [&lt;ulink linkID="1027499" linkType="Reference"&gt;1027499&lt;/ulink&gt;]. In January 2008, a phase II trial began for its use in postherpetic neuralgia [&lt;ulink linkID="877912" linkType="Reference"&gt;877912&lt;/ulink&gt;]; the study was completed in September 2008 [&lt;ulink linkID="877912" linkType="Reference"&gt;877912&lt;/ulink&gt;]. In March 2014, the drug was listed as being in phase II development for PHN  [&lt;ulink linkID="1533335" linkType="Reference"&gt;1533335&lt;/ulink&gt;]; in September 2015, the drug was still listed as in phase II development [&lt;ulink linkID="1691817" linkType="Reference"&gt;1691817&lt;/ulink&gt;]. In March 2016, Crescita  expected to receive feedback from the FDA in the second quarter of 2016 on the clinical and regulatory requirements for the development of the drug  in neuropathic pain [&lt;ulink linkID="1740934" linkType="Reference"&gt;1740934&lt;/ulink&gt;]. By May 2016, Crescita   received written feedback from the US FDA. The FDA requested  extensive clinical and non-clinical programs for the development of Flexicaine [&lt;ulink linkID="1760909" linkType="Reference"&gt;1760909&lt;/ulink&gt;]. However, not further development has been reported for this indication for some time.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;An US NDA was filed in November 2003. In February 2004, the FDA accepted the submission for filing [&lt;ulink linkID="644099" linkType="Reference"&gt;644099&lt;/ulink&gt;], [&lt;ulink linkID="644113" linkType="Reference"&gt;644113&lt;/ulink&gt;]. The peel was approved by the FDA in June 2006 for use as a local anesthetic on intact skin before various superficial dermatological procedures such as dermal filler procedures, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal [&lt;ulink linkID="877913" linkType="Reference"&gt;877913&lt;/ulink&gt;].  In mid-2007, the peel was expected to be launched by &lt;ulink linkID="16350" linkType="Company"&gt;Galderma&lt;/ulink&gt; in the second half of 2007 [&lt;ulink linkID="877913" linkType="Reference"&gt;877913&lt;/ulink&gt;]. By February 2008,  the peel had been launched for use in superficial cosmetic procedures  in the US [&lt;ulink linkID="878158" linkType="Reference"&gt;878158&lt;/ulink&gt;]. In March 2008, Galderma expected to file the product for regulatory approval in the main worldwide market in 2008 [&lt;ulink linkID="883528" linkType="Reference"&gt;883528&lt;/ulink&gt;]. In April 2011, it was reported that the drug had not been available in the US since 2008 due to manufacturing issues. By that time, Galderma had taken on manufacturing of the drug and was expected to provide the FDA with the information needed to re-launch the drug in the US [&lt;ulink linkID="1184798" linkType="Reference"&gt;1184798&lt;/ulink&gt;]. In February 2012, the US approval and launch of the drug by Galderma was expected by the end of that year [&lt;ulink linkID="1259610" linkType="Reference"&gt;1259610&lt;/ulink&gt;]. Later that month, the FDA accepted the sNDA submitted by Galderma and set  PDUFA date as April 16, 2012, and launch was expected  in the second half of 2012  [&lt;ulink linkID="1264879" linkType="Reference"&gt;1264879&lt;/ulink&gt;]. In April 2012, Galderma received a complete response letter from the FDA for the sNDA    [&lt;ulink linkID="1281322" linkType="Reference"&gt;1281322&lt;/ulink&gt;]. In May 2012, Galderma  submitted additional  information to the FDA, relating to  manufacturing, stability data and  proposed labeling revisions. At that time, a 4-month review period was expected [&lt;ulink linkID="1288247" linkType="Reference"&gt;1288247&lt;/ulink&gt;]. In October 2012, sNDA was approved [&lt;ulink linkID="1333522" linkType="Reference"&gt;1333522&lt;/ulink&gt;]. In March 2013, the drug was launched in the US by its marketing partner Galderma Laboratories LP [&lt;ulink linkID="1390467" linkType="Reference"&gt;1390467&lt;/ulink&gt;]. In April 2017, Taro would be involved with Crescita's plans to file for US approval for the enhanced formulation [&lt;ulink linkID="1921282" linkType="Reference"&gt;1921282&lt;/ulink&gt;]. In March 2018, the drug was re-launched in the US by Taro Pharmaceuticals [&lt;ulink linkID="2018265" linkType="Reference"&gt;2018265&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;By May 2009, ZARS had filed  an MAA in a number of European countries [&lt;ulink linkID="1027499" linkType="Reference"&gt;1027499&lt;/ulink&gt;]. In April 2011, ZARS planned to file for approval in multiple European Union  countries in mid-2011 [&lt;ulink linkID="1184798" linkType="Reference"&gt;1184798&lt;/ulink&gt;]. In July 2011, the European regulatory agencies validated the MAA in  the European Union. At that time, Nuvo expected the drug approval in 2012; thereafter, the MAA would be transferred to  Galderma for launch [&lt;ulink linkID="1205423" linkType="Reference"&gt;1205423&lt;/ulink&gt;].  In February 2012,  EU approval and launch of the drug by Galderma was expected by the end of that year [&lt;ulink linkID="1259610" linkType="Reference"&gt;1259610&lt;/ulink&gt;]. In November 2012, the product was approved in Spain by Galderma [&lt;ulink linkID="1362499" linkType="Reference"&gt;1362499&lt;/ulink&gt;]; by March 2016, the drug was discontinued in Spain [&lt;ulink linkID="2127273" linkType="Reference"&gt;2127273&lt;/ulink&gt;]. In December 2012, the drug was approved in France [&lt;ulink linkID="1352779" linkType="Reference"&gt;1352779&lt;/ulink&gt;]. Later that month, the company planned to receive a response to MAA in the first half of 2012  and planned to launch the drug in the second half of 2012 [&lt;ulink linkID="1264879" linkType="Reference"&gt;1264879&lt;/ulink&gt;]. In May 2012,  a positive opinion was received from the European Decentralized  Procedure for the approval of the drug from the German Federal  Institute for Drugs and Medical Devices (BfArM) [&lt;ulink linkID="1287914" linkType="Reference"&gt;1287914&lt;/ulink&gt;]. In July 2012, Galderma received marketing authority in three EU countries with launch planned in the first half of 2013. Nuvo expected to receive marketing approval for the remaining 13 EU countries over the next 12 months [&lt;ulink linkID="1309787" linkType="Reference"&gt;1309787&lt;/ulink&gt;]. By January 2013, Nuvo Research had filed for approval in the UK [&lt;ulink linkID="1354580" linkType="Reference"&gt;1354580&lt;/ulink&gt;]. By March 2013,  the drug was expected to be launched in the EU by its marketing partner Galderma Laboratories LP, in April 2013 [&lt;ulink linkID="1396818" linkType="Reference"&gt;1396818&lt;/ulink&gt;].  In April 2013, the drug was launched in European countries by Galderma [&lt;ulink linkID="1408247" linkType="Reference"&gt;1408247&lt;/ulink&gt;].  In October 2013,    approvals for additional European countries were expected   in the  'next two years' [&lt;ulink linkID="1486479" linkType="Reference"&gt;1486479&lt;/ulink&gt;].    By July 2015, the drug was launched in France [&lt;ulink linkID="2127270" linkType="Reference"&gt;2127270&lt;/ulink&gt;]. In April 2019, the drug was only available in the US, Italy and Brazil and presumably withdrawn in the regions where it was previously launched [&lt;ulink linkID="2145520" linkType="Reference"&gt;2145520&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2011, Galderma filed marketing applications in Switzerland  [&lt;ulink linkID="1264879" linkType="Reference"&gt;1264879&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In February 2012, Galderma's New Drug submission was accepted by Health Canada [&lt;ulink linkID="1264879" linkType="Reference"&gt;1264879&lt;/ulink&gt;]. In April 2013, the drug was expected to be launched in Canada in 2014  [&lt;ulink linkID="1408247" linkType="Reference"&gt;1408247&lt;/ulink&gt;]. By December 2015, Pliaglis had been approved and launched in  Canada  [&lt;ulink linkID="1723148" linkType="Reference"&gt;1723148&lt;/ulink&gt;]. In April 2019, the drug was only available in the US, Italy and Brazil and presumably withdrawn in the regions where it was previously launched [&lt;ulink linkID="2145520" linkType="Reference"&gt;2145520&lt;/ulink&gt;]. In May 2019, Crescita planned to re-launch the drug in Canada in the second half of 2019 [&lt;ulink linkID="2169893" linkType="Reference"&gt;2169893&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;In September 2011, Galderma filed marketing applications Brazil  [&lt;ulink linkID="1264879" linkType="Reference"&gt;1264879&lt;/ulink&gt;]. In October 2013,  the drug was approved in Brazil  and was expected to be launched in  early 2014 [&lt;ulink linkID="1486479" linkType="Reference"&gt;1486479&lt;/ulink&gt;].  In March 2014, the drug was launched in Brazil [&lt;ulink linkID="1551995" linkType="Reference"&gt;1551995&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2011, Galderma was expected to file for marketing approval in  other South American countries [&lt;ulink linkID="1264879" linkType="Reference"&gt;1264879&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2011, the drug had been launched in Argentina by Galderma [&lt;ulink linkID="1408247" linkType="Reference"&gt;1408247&lt;/ulink&gt;]. In April 2019, the drug was only available in the US, Italy and Brazil and presumably withdrawn in the regions where it was previously launched [&lt;ulink linkID="2145520" linkType="Reference"&gt;2145520&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2015, Pliaglis had been approved and launched in  Mexico [&lt;ulink linkID="1723148" linkType="Reference"&gt;1723148&lt;/ulink&gt;]. In September 2016, Crescita received approval, presumably re-approval, for commercial sale of Pliaglis in Mexico and subsequently launched  [&lt;ulink linkID="1794951" linkType="Reference"&gt;1794951&lt;/ulink&gt;]. In April 2019, the drug was only available in the US, Italy and Brazil and presumably withdrawn in the regions where it was previously launched [&lt;ulink linkID="2145520" linkType="Reference"&gt;2145520&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;In September 2011, Galderma was expected to file for marketing approval in   South Africa [&lt;ulink linkID="1264879" linkType="Reference"&gt;1264879&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In September 2011, Galderma  was expected to file for marketing approval in  select Asian countries [&lt;ulink linkID="1264879" linkType="Reference"&gt;1264879&lt;/ulink&gt;]. In April 2013, the drug was expected to be launched in Asian countries in  2015 [&lt;ulink linkID="1408247" linkType="Reference"&gt;1408247&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2011, Galderma  was expected to file for marketing approval in  Australia [&lt;ulink linkID="1264879" linkType="Reference"&gt;1264879&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Postherpetic neuralgia&lt;/subtitle&gt;By April 2010, a phase IIa efficacy trial had been completed. The drug showed significant decrease in pain compared to placebo [&lt;ulink linkID="1190068" linkType="Reference"&gt;1190068&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2008, a  randomized, double-blind, crossover assignment, safety/efficacy phase II trial (&lt;ulink linkID="7862" linkType="Protocol"&gt;NCT00609323&lt;/ulink&gt;,  SCP-403) was initiated in the US in patients with postherpetic neuralgia (n = 18). Primary outcome measures were patient-rated pain intensity,  area and intensity of allodynia, and patient global impression of change.  At that time, the study was expected to be completed in  July 2008 [&lt;ulink linkID="877912" linkType="Reference"&gt;877912&lt;/ulink&gt;]. In September 2008, the study was completed [&lt;ulink linkID="877912" linkType="Reference"&gt;877912&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Superficial cosmetic procedures&lt;/subtitle&gt;By January 2006, the peel had been tested in several trials for superficial cosmetic procedures, many of them prospective, randomized and double-blinded, enrolling over 850 patients [&lt;ulink linkID="644099" linkType="Reference"&gt;644099&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2005, data from a multicenter, randomized, double-blind, placebo-controlled, 30-patient study showed that the peel reduced pain levels from laser-assisted tattoo removal. Adequate anesthesia and reduced pain were reported at 70% of peel treatment sites, compared to 10% of placebo treatment sites. One occurrence of moderate-to-severe erythema was noted at both a peel and placebo treatment site [&lt;ulink linkID="644408" linkType="Reference"&gt;644408&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2003, data from two randomized, double-blind, placebo-controlled trials of the peel in 60 and 40 patients, respectively, undergoing laser treatment for leg veins, were published. The first trial assessed 30 or 60 min application of the cream, while the second trial assessed 60 or 90 min application of the cream. The peel was shown to give safe and effective anesthesia when applied for at least 60 min [&lt;ulink linkID="644411" linkType="Reference"&gt;644411&lt;/ulink&gt;]. In 2004, similar data were published [&lt;ulink linkID="644409" linkType="Reference"&gt;644409&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2003, data from a randomized, placebo-controlled, 20-patient trial of the peel were published. A painless procedure was noted in 50 and 65% (independent observer and investigator scores, respectively) of patients undergoing nonablative laser treatment after peel anesthesia, compared to 0 and 5% of those undergoing treatment after placebo anesthesia [&lt;ulink linkID="644412" linkType="Reference"&gt;644412&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2002, data from  a double-blind trial of the  peel were published. A total of 20 patients were treated with the peel or EMLA cream prior to full-face single-pass CO2 laser resurfacing. Pain scores were lower in those treated with the peel, with adverse effects limited to transient mild erythema and skin blanching [&lt;ulink linkID="644420" linkType="Reference"&gt;644420&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2002, data from  a double-blind trial of the  peel were published. A total of 60 patients were treated for 20, 30 or 60 min with the peel or placebo prior to laser treatment for facial telangiectases or port-wine stains. All patients experienced significant  pain reduction with the peel with adverse effects limited to transient mild erythema. Application durations of 20 or 30 min were as effective as 60 min [&lt;ulink linkID="644421" linkType="Reference"&gt;644421&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In June 2010, the EMA's Pediatric Committee adopted an opinion on the refusal of a pediatric investigation plan for the drug in the therapeutic area of anaesthesiology. The committee subsequently granted a product-specific waiver on the grounds that the drug did not represent a significant therapeutic benefit over existing treatments for pediatric patients [&lt;ulink linkID="1109144" linkType="Reference"&gt;1109144&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By mid-2007, &lt;ulink linkID="16350" linkType="Company"&gt;Galderma Pharma&lt;/ulink&gt; acquired promotion and distribution  rights for &lt;ulink linkID="1005570" linkType="Company"&gt;&lt;/ulink&gt;Pliaglis in the US and Canada [&lt;ulink linkID="877913" linkType="Reference"&gt;877913&lt;/ulink&gt;], [&lt;ulink linkID="878158" linkType="Reference"&gt;878158&lt;/ulink&gt;], [&lt;ulink linkID="883528" linkType="Reference"&gt;883528&lt;/ulink&gt;]. In March 2008, Galderma acquired exclusive promotion and distribution rights for the rest of the world [&lt;ulink linkID="883528" linkType="Reference"&gt;883528&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2000, &lt;ulink linkID="17332" linkType="Company"&gt;Johnson &amp;amp; Johnson&lt;/ulink&gt; (J&amp;amp;J) was granted exclusive manufacturing and marketing rights to the cream. ZARS was to be responsible for product development costs and would receive development- and approval-based milestones, plus royalties, from J&amp;amp;J [&lt;ulink linkID="644099" linkType="Reference"&gt;644099&lt;/ulink&gt;]. However, by mid-2007, J&amp;amp;J  no longer had marketing rights to the product [&lt;ulink linkID="877913" linkType="Reference"&gt;877913&lt;/ulink&gt;], [&lt;ulink linkID="878158" linkType="Reference"&gt;878158&lt;/ulink&gt;]. At that time, a marketing partner for the rest of the world was still to be determined [&lt;ulink linkID="877913" linkType="Reference"&gt;877913&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1120227">Crescita Therapeutics Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2019-04-01T00:00:00.000Z</StatusDate><Source id="2145520" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1092247">Cantabria Labs Spain</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2019-04-25T00:00:00.000Z</StatusDate><Source id="2145520" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27572">Taro Pharmaceuticals Inc (Canada)</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2018-03-29T00:00:00.000Z</StatusDate><Source id="2018265" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1120227">Crescita Therapeutics Inc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2019-04-01T00:00:00.000Z</StatusDate><Source id="2145520" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1120227">Crescita Therapeutics Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2016-03-01T00:00:00.000Z</StatusDate><Source id="1739318" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1092247">Cantabria Labs Spain</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2019-04-25T00:00:00.000Z</StatusDate><Source id="2145520" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1092247">Cantabria Labs Spain</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2019-04-25T00:00:00.000Z</StatusDate><Source id="2145520" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1092247">Cantabria Labs Spain</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2019-04-25T00:00:00.000Z</StatusDate><Source id="2145520" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16350">Galderma SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2016-03-31T00:00:00.000Z</StatusDate><Source id="2127273" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1120227">Crescita Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2019-04-01T00:00:00.000Z</StatusDate><Source id="2145520" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1120227">Crescita Therapeutics Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2019-04-01T00:00:00.000Z</StatusDate><Source id="2145520" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1120227">Crescita Therapeutics Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2019-04-01T00:00:00.000Z</StatusDate><Source id="2145520" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1120227">Crescita Therapeutics Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2019-04-01T00:00:00.000Z</StatusDate><Source id="2145520" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1120227">Crescita Therapeutics Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2019-04-01T00:00:00.000Z</StatusDate><Source id="2145520" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16350">Galderma SA</Company><Country id="EU">EU</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="328">Topical anesthesia</Indication><StatusDate>2019-04-01T00:00:00.000Z</StatusDate><Source id="2145520" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16350">Galderma SA</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="328">Topical anesthesia</Indication><StatusDate>2019-04-01T00:00:00.000Z</StatusDate><Source id="2145520" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16350">Galderma SA</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="328">Topical anesthesia</Indication><StatusDate>2015-12-22T00:00:00.000Z</StatusDate><Source id="1723148" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16350">Galderma SA</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="328">Topical anesthesia</Indication><StatusDate>2019-04-01T00:00:00.000Z</StatusDate><Source id="2145520" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16350">Galderma SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="328">Topical anesthesia</Indication><StatusDate>2019-04-01T00:00:00.000Z</StatusDate><Source id="2145520" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16350">Galderma SA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="328">Topical anesthesia</Indication><StatusDate>2015-12-22T00:00:00.000Z</StatusDate><Source id="1723148" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16350">Galderma SA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="328">Topical anesthesia</Indication><StatusDate>2019-04-01T00:00:00.000Z</StatusDate><Source id="2145520" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16350">Galderma SA</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="328">Topical anesthesia</Indication><StatusDate>2015-12-22T00:00:00.000Z</StatusDate><Source id="1723148" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1120227">Crescita Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3300">Postherpetic neuralgia</Indication><StatusDate>2019-07-02T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1120227">Crescita Therapeutics Inc</Company><Country id="IT">Italy</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2019-04-25T00:00:00.000Z</StatusDate><Source id="2145520" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1120227">Crescita Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2017-04-25T00:00:00.000Z</StatusDate><Source id="1921282" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1005570">ZARS Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3300">Postherpetic neuralgia</Indication><StatusDate>2008-01-31T00:00:00.000Z</StatusDate><Source id="877912" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1005570">ZARS Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2008-02-19T00:00:00.000Z</StatusDate><Source id="878158" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1005570">ZARS Pharma Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2009-05-12T00:00:00.000Z</StatusDate><Source id="1027499" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16350">Galderma SA</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2008-02-19T00:00:00.000Z</StatusDate><Source id="878158" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16350">Galderma SA</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2008-12-31T00:00:00.000Z</StatusDate><Source id="1264879" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1005570">ZARS Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2008-12-31T00:00:00.000Z</StatusDate><Source id="1264879" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15713">Nuvo Pharmaceuticals Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2011-05-13T00:00:00.000Z</StatusDate><Source id="1027499" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16350">Galderma SA</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2003-11-30T00:00:00.000Z</StatusDate><Source id="644099" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16350">Galderma SA</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2006-06-29T00:00:00.000Z</StatusDate><Source id="1484863" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16350">Galderma SA</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2012-07-19T00:00:00.000Z</StatusDate><Source id="1309787" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16350">Galderma SA</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2011-09-30T00:00:00.000Z</StatusDate><Source id="1264879" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16350">Galderma SA</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2013-10-10T00:00:00.000Z</StatusDate><Source id="1486479" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16350">Galderma SA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2012-02-10T00:00:00.000Z</StatusDate><Source id="1264879" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15713">Nuvo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2011-05-13T00:00:00.000Z</StatusDate><Source id="1191539" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15713">Nuvo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3300">Postherpetic neuralgia</Indication><StatusDate>2011-05-13T00:00:00.000Z</StatusDate><Source id="1191539" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15713">Nuvo Pharmaceuticals Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2015-12-22T00:00:00.000Z</StatusDate><Source id="1723148" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15713">Nuvo Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2015-12-22T00:00:00.000Z</StatusDate><Source id="1723148" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15713">Nuvo Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2013-01-02T00:00:00.000Z</StatusDate><Source id="1354580" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15713">Nuvo Pharmaceuticals Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2012-07-19T00:00:00.000Z</StatusDate><Source id="1309787" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15713">Nuvo Pharmaceuticals Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2012-02-21T00:00:00.000Z</StatusDate><Source id="1264879" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27572">Taro Pharmaceuticals Inc (Canada)</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2017-04-25T00:00:00.000Z</StatusDate><Source id="1921282" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16350">Galderma SA</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2012-12-11T00:00:00.000Z</StatusDate><Source id="1352779" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16350">Galderma SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2012-11-06T00:00:00.000Z</StatusDate><Source id="1362499" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040947">Galderma Laboratories LP</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2015-12-22T00:00:00.000Z</StatusDate><Source id="1723148" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040947">Galderma Laboratories LP</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2015-12-22T00:00:00.000Z</StatusDate><Source id="1723148" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16350">Galderma SA</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2014-03-31T00:00:00.000Z</StatusDate><Source id="1551995" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16350">Galderma SA</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2011-12-31T00:00:00.000Z</StatusDate><Source id="1408247" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16350">Galderma SA</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2015-07-06T00:00:00.000Z</StatusDate><Source id="2127270" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040947">Galderma Laboratories LP</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2013-03-11T00:00:00.000Z</StatusDate><Source id="1390467" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16350">Galderma SA</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2013-04-23T00:00:00.000Z</StatusDate><Source id="1408247" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16350">Galderma SA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2011-09-30T00:00:00.000Z</StatusDate><Source id="1264879" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1120227">Crescita Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3300">Postherpetic neuralgia</Indication><StatusDate>2016-03-01T00:00:00.000Z</StatusDate><Source id="1739318" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15713">Nuvo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2015-12-22T00:00:00.000Z</StatusDate><Source id="1723148" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040947">Galderma Laboratories LP</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2014-02-11T00:00:00.000Z</StatusDate><Source id="2169931" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1120227">Crescita Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2016-03-01T00:00:00.000Z</StatusDate><Source id="1739318" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1120227">Crescita Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2016-03-01T00:00:00.000Z</StatusDate><Source id="1739318" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1120227">Crescita Therapeutics Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2016-03-01T00:00:00.000Z</StatusDate><Source id="1739318" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1120227">Crescita Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2017-04-25T00:00:00.000Z</StatusDate><Source id="1921282" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1120227">Crescita Therapeutics Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2016-03-01T00:00:00.000Z</StatusDate><Source id="1739318" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1005570">ZARS Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2003-11-30T00:00:00.000Z</StatusDate><Source id="644099" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1005570">ZARS Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2002-11-30T00:00:00.000Z</StatusDate><Source id="644421" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1005570">ZARS Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="328">Topical anesthesia</Indication><StatusDate>2006-07-06T00:00:00.000Z</StatusDate><Source id="677389" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01747"><Name>Sodium channel</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2151845" linkType="reference" linkID="2151845"&gt;2151845&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1092247">Cantabria Labs Spain</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1120227">Crescita Therapeutics Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="15713">Nuvo Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17332">Johnson &amp; Johnson</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18477">Nestle SA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="27570">Taro Pharmaceutical Industries Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>2</CountInactive><CountTotal>3</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCN(CC)CC(=O)Nc1c(cccc1C)C</Smiles><Smiles>CCCCNc1ccc(cc1)C(=O)OCCN(C)C.CCN(CC)CC(=O)Nc1c(cccc1C)C</Smiles><Smiles>CCCCNc1ccc(cc1)C(=O)OCCN(C)C</Smiles></StructureSmiles><Deals><Deal id="111947" title="Galderma to market ZARS' Pliaglis worldwide                  "/><Deal id="126293" title="J&amp;J to commercialize TetraPeel from ZARS "/><Deal id="238116" title="Taro to develop and commercialize Crescita's Pliaglis for local dermal anesthesia in US and ex-Canada and Mexico"/><Deal id="255325" title="Cantabria to commercialize Crescita's Pliaglis for dermatology in Italy, Portugal, France and Spain"/></Deals><PatentFamilies><PatentFamily id="1629148" number="WO-2011088333" title="Solid-forming local anesthetic formulations for pain control"/><PatentFamily id="2195828" number="WO-00122907" title="Drug Delivery Of Phase Changing Formulation"/><PatentFamily id="2433063" number="WO-2010129542" title="Methods of treating pains associated with neuroma, nerve entrapment, and other conditions"/><PatentFamily id="2440668" number="WO-2013001073" title="New stable anesthetic composition for reducing skin reactions"/><PatentFamily id="2929246" number="WO-2015061910" title="Topical formulations, systems, and methods"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>4</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Crescita Therapeutics Inc" id="1120227"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nuvo Pharmaceuticals Inc" id="15713"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nestle SA" id="18477"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>